Abbvie RINVOQ gets European Commission nod for treatment of Active Non-Radiographic Axial Spondyloarthritis in adults Ruchika Sharma31 July 2022 11:30 AM ISTAbbvie RINVOQ gets European Commission nod for Adults with Active Non-Radiographic Axial Spondyloarthritis
AbbVie, iSTAR Medical collaborate to develop, commercialize MINIject device for Glaucoma Ruchika Sharma21 July 2022 3:30 PM ISTUnder the terms of the agreement, iSTAR Medical will receive a $60M non-dilutive upfront payment and will continue to develop and commercialize...
AbbVie seeks EMA approval for Atogepant for prophylaxis treatment of Migraine Ruchika Sharma19 July 2022 1:45 PM ISTAtogepant is an orally administered, CGRP receptor antagonist (gepant) specifically developed for the prophylaxis treatment of migraine.
AbbVie files sNDA to USFDA for Atogepant for chronic migraine treatment Ruchika Sharma22 Jun 2022 1:30 PM ISTNorth Chicago, Ill.: AbbVie has announced that the company has submitted a supplemental New Drug Application (sNDA) for atogepant (QULIPTA) to the...
USFDA nod to AbbVie SKYRIZI for Crohn's disease treatment Ruchika Sharma18 Jun 2022 1:30 PM ISTCrohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal (or digestive) tract, causing persistent...
AbbVie, Cugene ink pact for CUG252 for treatment of autoimmune, inflammatory diseases Ruchika Sharma17 May 2022 10:00 AM ISTUnder the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and...
AbbVie awarded with Great Place to Work Certification Ruchika Sharma26 Dec 2021 10:30 AM ISTNew Delhi: AbbVie in India has recently been awarded a Great Place to Work Certification, recognizing AbbVie's culture of driving breakthroughs by...
AbbVie gets Europen Commission nod for SKYRIZI to treat adults with Active Psoriatic Arthritis Ruchika Sharma18 Nov 2021 10:00 AM ISTNorth Chicago, III: AbbVie has recently announced that the European Commission (EC) has approved SKYRIZI (risankizumab, 150 mg, subcutaneous injection...
AbbVie, Sosei ink drug discovery deal worth USD 1 billion Ruchika Sharma26 Jun 2020 12:46 PM ISTThe partnership will initially focus on the discovery of novel small molecules, targeting inflammatory and autoimmune diseases, the companies said in...
